No products in the cart.
Pre-made Abagovomab benchmark antibody (Whole mAb, anti-CA125/MUC16 therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-001
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Abagovomab biosimilar, Whole Mab: Anti-CA125/MUC16 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Abagovomab is a mouse anti-idiotype monoclonal antibody whose variable epitope mirrors a tumour antigen (CA-125) highly expressed in the epithelial ovarian cancer. Abagovomab does not bind directly to CA-125, but it works as a “surrogate” antigen, enabling the immune system to identify and attack tumour cells displaying the CA-125 protein. Through this, it is hoped that the body’s immune system may be able to combat any remaining individual tumour cells and thus prevent recurrence of the disease.
| Products Name (INN Index) | Pre-Made Abagovomab biosimilar, Whole Mab: Anti-CA125/MUC16 therapeutic antibody |
|---|---|
| INN Name | Abagovomab |
| Target | MUC16 |
| Format | Whole mAb |
| Derivation | Mouse |
| Species Reactivity | Human(H) |
| CH1 Isotype | IgG1(IG-GAMMA-1) |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2006 |
| Year Recommended | 2007 |
| Companies | Menarini |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Ovarian cancer,Pancreatic cancer |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CA125/MUC16 |
| Package |
Previous slide
Next slide
